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Abstract
Background: Inflammaging is a persistent, low−grade, sterile, nonresolving inflammatory state, associated with the
senescence of the immune system. Such condition downregulates both innate and adaptive immune responses
during chronic disorders as type II diabetes, cancer and hemodialysis, accounting for their susceptibility to
infections, malignancy and resistance to vaccination.
Aim of this study was to investigate hemodialysis inflammaging, by evaluating changes of several hemodialysis
treatments on indoleamine 2,3-dioxygenase-1 activity and nitric oxide formation.
Methods: We conducted a randomized controlled observational crossover trial. Eighteen hemodialysis patients
were treated with 3 different hemodialysis procedures respectively: 1) Low−flux bicarbonate hemodialysis, 2) Low
−flux bicarbonate hemodialysis with vitamin E − loaded dialyzers, and 3) Hemodialfitration. The control group
consisted of 14 hospital staff healthy volunteers. Blood samples were collected from all 18 hemodialysis patients
just after the long interdialytic interval, at the end of each hemodialysis treatment period.
Results: Hemodialysis kynurenine and kynurenine/L − tryptophan blood ratio levels were significantly higher, when
compared to the control group, indicating an increased indoleamine 2,3-dioxygenase-1 activity in hemodialysis
patients. At the end of the low−flux bicarbonate hemodialysis with vitamin E − loaded dialyzers period, L −
tryptophan serum levels remained unchanged vs both low−flux bicarbonate hemodialysis and hemodialfitration.
Kynurenine levels instead decreased, resulting in a significant reduction of kynurenine/L − tryptophan blood ratio
and indoleamine 2,3-dioxygenase-1 activity, when matched to both low−flux bicarbonate hemodialysis and HDF
respectively. Serum nitric oxide control group levels, were significantly lower when compared to all hemodialysis
patient groups. Interestingly, low−flux bicarbonate hemodialysis with vitamin E − loaded dialyzers nitric oxide serum
levels from venous line blood samples taken 60 min after starting the hemodialysis session were significantly lower
vs serum taken simultaneously from the arterial blood line.
Conclusions: The treatment with more biocompatible hemodialysis procedure as low−flux bicarbonate
hemodialysis with vitamin E − loaded dialyzers, reduced indoleamine 2,3-dioxygenase-1 activity and nitric oxide
formation when compared to both low−flux bicarbonate hemodialysis and hemodialfitration. These data suggest
that low−flux bicarbonate hemodialysis with vitamin E − loaded dialyzers lowering hemodialysis inflammaging,
could be associated to changes of proinflammatory signalling a regulated molecular level.
Trial registration: NCT Number: NCT02981992; Other Study ID Numbers: 20100014090. First submitted: November
26, 2016. First posted: December 5, 2016. Last Update Posted: December 5, 2016.
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Background
Inflammaging is a new field of clinical research orientated
to study age–related persistent, low−grade, sterile and non
−resolving inflammatory states in chronic diseases such as
type II diabetes, obesity and other metabolic disorders [1].
Such clinical states are mainly sustained by macrophage
proinflammatory activation. Increased expression of IDO1
appears to modulate macrophage differentiation towards
the M2 phenotype [2]. Nevertheless, recent studies suggest
a deficit of macrophage polarization capacity in aged mice
[3]. Although an M2–like macrophage shift is predictive
of successful biomaterial implant, it was observed a local
M1 skewed host response at the site of effective of poly-
propylene mesh implants in aged experimental animals
[3]. Data on macrophage polarization during hemodialyzer
blood interaction, are not currently available. The known
detrimental effect of macrophage triggering during
chronic hemodialysis [4] is also associated to the increase
of blood NO levels, reducing both native and adaptive im-
mune responses [5, 6].
Uremia is characterized by chronic systemic inflamma-
tion and chronic activation of the immune system, often
followed by immune deficiency [7, 8]. Impaired immune
response in uremic patients is mainly characterized by
innate and adaptive immune regulation with a T cell
number decrease, function loss [9], and complement
dysregulation [10, 11], which results in a frequent sus-
ceptibility to sepsis [12], malignancy [13], resistance to
vaccination [14] and cardiovascular diseases [15]. Oxida-
tive stress and chronic inflammation are increasingly
appearing as relevant atherosclerosis and cardiovascular
mortality contributors in hemodialysis patients [16]. Ac-
cumulating evidence on end−stage renal disease patients
show that uremia−associated immune deficiency is asso-
ciated to chronic inflammation and immunological aging
[17]. IDO1 is a unique dioxygenase class member, cata-
lysing L−Trp to its product Kyn [18]. IDO1 and Kyn
have a significant function on T cell immunosuppres-
sion, Treg activation, and inhibition of natural killer cells
[19]. Induction of IDO1 transcription and function, asso-
ciated to Treg suppressive activity, is increased in chronic
hemodialysis inflammation [18–20].
Although NO is a small, easily diffusible molecule by dia-
lysis, its levels significantly increase during hemodialysis
[21, 22]. It might be related to the hyperactivation of
macrophage activity by both uremia and the hemodialysis
procedure itself [22]. There is a growing body of evidence
suggesting that hemodialysis is characterized by excessive
oxidative stress status, resulting from the loss of antioxi-
dants during hemodialysis procedures or dietary restric-
tions, and the accumulation of oxidative products.
Deficiency of vitamin C and selenium, reduced intracellular
levels of vitamin E, and the increased synthesis of reactive
oxygen species and nitrogen species as NO, are relevant
mechanisms associated with hemodialysis excess of oxida-
tive stress [23].
Since 2004, vitamin E has been submitted as drug
therapy for hemodialysis microinflammation [24], and
solid data are available on lowering oxidative stress and
inflammation obtained using VIT−E dialyzers [25, 26].
We also observed a vast Treg number in hemodialysis
patients, suggesting an increased immune tolerance
when compared to controls [27]. However, little experi-
mental data are available on the role that VIT−E have in
regulating the immune response associated to IDO1 ac-
tivity and NO formation. A monocyte−derived cell ex-
perimental model (THP−1), found alpha-tocopherol (a
vitamin E analogue) to attenuate L−Trp and IDO1 re-
lated, apoptosis after induction by IFN−γ [28]. Currently,
hemodialysis data on the role vitamin E on NO forma-
tion have are not available. Moreover, still controversial
is the role of VIT−E hemodialysis in atherosclerosis,
when complement regulation [29], oxidative stress and
inflammation prevention are specific endpoints [19].
Large population−based studies associated high dietary
vitamin E supplements with a lower risk of coronary
heart disease. Nevertheless, interventional studies on
population with large and/or maintenance hemodialysis
patients, failed to show any beneficial effect of vitamin E
oral intake in the development of coronary artery disease
[30]. More consistent data are published on oxidative
stress in the course of treatment with VIT−E, showing
improved biocompatibility and reduced reactive oxygen
species formation [30]. At present, papers on both blood
IDO1 activity and NO formation in hemodialysis pa-
tients and related dialysis procedures have not been pub-
lished. Aim of this study was to investigate the
mechanisms of hemodialysis inflammaging, comparing
IDO1 blood activity and NO formation in patients
treated by standard low−flux polysulfone BHD, low−flux
VIT−E hemodialysis, and polysulfone HDF.
Methods
Study design and rationale
This study was a randomized controlled observational
crossover trial. Eighteen patients randomly sampled from
our hemodialysis unit, have been included in the study.
Exclusion criteria included recent illness (within the
previous 2 months), significant anemia (Hb < 10 g/dl),
autoimmune disease, current/previous (6 months) im-
munosuppressive treatment, but also systemic diseases
such as diabetes, vasculitis, amyloidosis, rheumatic disease;
HBV, HCV, HIV positivity, other active viral and/or bac-
terial infection, active cancer or after remission and previ-
ous transplantation.
All 18 chronic hemodialysis patients have been on a
thrice−weekly hemodialysis regimen for at least 6
months, treated with standard low−flux polysulfone
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dialysis. In random sequence hemodialysis patients
underwent a 4−hour thrice−weekly, 3−month period of
a) standard low–flux bicarbonate hemodialysis with
polysulfone membrane dialyzers, (BHD; FX10 Low−Flux,
Helixone® membrane, ©Fresenius Medical Care AG &
Co. KGaA, Bad Hamburg, Germany), b) HDF (pre−dilu-
tion 70 ± 12 ml/min) with polysulfone membrane dia-
lyzers (FX100 High−Flux, Helixone® membrane,
©Fresenius Medical Care AG & Co. KGaA, Bad Ham-
burg, Germany) and c) standard low–flux VIT−E BHD
(VitabranE® membrane E18, Asahi Kasei Kuraray Med-
ical Co., Japan). Blood samples were taken at the end of
the long interdialytic interval, at the beginning and at
the end of each 3–month period of the study respect-
ively. In order to evaluate the interference of the vitamin
E–loaded membrane dialyzers on NO serum levels,
blood samples were also taken simultaneously from ar-
terial and venous lines at the beginning and 60 minutes
after starting the same hemodialysis session and at the
end of the last long interdialytic interval of each 3–
month period of the study. Current therapy remained
unchanged for the duration of the study. European Renal
Best Practice (ERBP) guidelines for anaemia in chronic
kidney disease (CKD) were applied [31]. In detail, intra-
venous iron supplements were administrated as sodium
ferric gluconate complex, or ferric caboxymaltose were
administrated at the end of a hemodialysis session ac-
cording to prescription, in order to maintain ferritin blood
levels ≤ 800 ng/ml and transferrin saturation > 20%.
Correction of hyperparathyroidism and hypertension
treatment remained unchanged throughout the study. A
control group of 14 hospital staff individuals, healthy for
at least 6 months, were also recruited. Participant charac-
teristics are summarized on Table 1.
Chromatographic determination of kynurenine and L −
tryptophan
Serum (1 ml) was deproteinized by 100 μl 30%
trichloroacetic acid (Sigma−Aldrich, Italy). An amount
(250 μl) of supernatant was added to 50 μl of aqueous
solution 49.4 μmol/l of theophilline as per Internal
Standard (IS, Sigma−Aldrich, Italy). For delayed analysis,
deproteinised samples were stored at -80 °C for at least
one month. Standard stock aqueous solutions (2.47
mmol/l for Kyn and 4.41 mmol/l for Trp, both from
Sigma−Aldrich, Italy) were prepared and kept frozen at
-80 °C. Working standard solutions were made by ap-
propriate dilution of a standard mixture.
HPLC method issued from separation conditions for
Kyn and L−Trp was developed by Zhen et al [32]. In the
present method, separation was achieved on HP1100 LC
system (Agilent Tecnologies S.p.A., Italy) using a column
Supelco C18 LC18DB (Sigma−Aldrich, Italy) (150 mm x
4.6 mm, particles size 5 μ) by isocratic elution (30 °C, 30
minutes). Mobile phase consisted of 50 mmol/l acetic-
acetate buffer pH 4,6 (Sigma−Aldrich, Italy) and Metha-
nol HPLC grade (VWR International PBI s.r.l, Italy) (95:
5 v/v) at a flow rate of 0.8 ml/min. Eluates were moni-
tored by DAD set at λ 360 nm for Kyn and λ 275 nm for
L−Trp and IS. Absorbancy at λ 220 nm and λ 302 nm
were also obtained, absorbance ratios were used for
identification and purity assessment of each peak. Sam-
ple injection was 50 μl.
IDO1 activity was assessed in sera as change of L−Trp
and its catabolic product Kyn (Kyn/Trp ratio), simultan-
eously measured using an isocratic RP HPLC method
with UV detection.
Total nitric oxide assay
We investigated the effects of dialysis treatment on NO
serum levels in peripheral blood. Blood samples were
obtained at the end of the long interdialytic interval of
the last 3−month hemodialysis treatment periods. More-
over, during the last 3−month session of each
hemodialysis treatment period, at the end of the long
interdialytic interval, blood specimens were also taken
60 minutes after the beginning of the same hemodialysis
session, simultaneously from the arterial and venous dia-
lysis lines. We measured NO by photometric analysis
with a nitrate/nitrite colorimetric assay kit (R&D Sys-
tems, Minneapolis, MN, USA). NO production was de-
termined as NO2
+ NO3
- with the Griess reagent after
reduction of nitrate, to nitrite with nitrate reductase. Al-
though several authors showed inflammation marker
and oxidative stress peaks after already 15–30 minutes
from the beginning of a hemodialysis session [33, 34],
we designed this study consistently with a previous
paper [26] where we found a significant variation of NO
serum levels for 60 minutes. Readings were at 540 nm,




Sex, M:F 6:8 10:8
Age, yearsa 55.6 ± 5.8 59.9 ± 7.3b
Time on HD, monthsa N/A 29.4 ± 17.1
ESRD cause, N:
Nephroangiosclerosis N/A 7
Polycystic kidney disease N/A 2
Interstitial nephritis N/A 1
Chronic glomerulonephritis N/A 3
Chronic pyelonephritis N/A 1
Unknown origin N/A 4
N number of patients, CON hospital staff healthy volunteers, HD hemodialysis;
a, data are M ± SD; ESRD, end-stage renal disease; b, P=NS vs CON; N/A
not applicable
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and baseline correction was carried out at 620 nm. The
sensitivity limit of the assay was 1.35 μmol/l.
C-reactive Protein
The CRP (n.v. ≤ 6 mg/dl) was measured by the local
hospital laboratory using the Latex C-Reactive Protein
immunoturbidimetric assay (Alpha Laboratories East-
leigh Hampshire, UK).
Statistical analysis
Data are presented as count or M ± SD and were ana-
lyzed by SPSS version 19.0 (Chicago, IL, USA). ANOVA
with Bonferroni analysis was performed on all dependent
variables. Percentage data were compared by X2 test to
assess p-value significance. Two-tailed tests were con-
ducted on all comparisons, and P < 0.05 was considered
significant.
Results
Table 1 shows demographic and clinical characteristics
of hemodialysis patients compared to the control group.
All patients were clinically stable, and hemodialysis Kt/V
was always ≥ 1.2. Any vascular access, i.e. autologous ar-
teriovenous fistula, arteriovenous graft or venous cath-
eter, showed patency and a regular flow of > 300 ml/min
during the study.
CRP was significantly higher in hemodialysis patients
(8.38 ± 7.22 mg/dl) when compared to controls (3.52 ±
1.57 mg/dl, P < 0.05). Serum CRP levels were not signifi-
cantly different among hemodialysis groups: BHD 9.23 ±
5.71 mg/dl, low−flux VIT−E 8.04 ± 4.02 mg/dl, HDF
7.87 ± 4.46 mg/dl.
IDO1 activity
Table 2 summarized the data of IDO1 activity, as Kyn,
Trp blood levels and Kyn/Trp ratio in controls and all
hemodialysis patients at the beginning and at the end of
the study respectively. Regardless to hemodialysis pro-
cedure, the Kyn/Trp ratio was significantly higher when
compared to controls (P < 0.01) showing an increased
IDO1 blood activity in hemodialysis patients. A signifi-
cantly increased IDO1 blood activity was also observed
regardless of hemodialysis procedure or hemofilter
membrane utilized when compared to controls.
L−Trp levels in hemodialysis patients were signifi-
cantly lower when compared to controls (P < 0.05),
whereas Kyn increased significantly in hemodialysis pa-
tients vs controls (P < 0.05).
However, different hemodialysis treatments influenced
IDO1 blood activity (Table 3). Treatment with VIT−E
reduced significantly IDO1 activity when compared to
treatment without vitamin E−loaded polysulfone mem-
branes, regardless of BHD (P < 0.05) or HDF treatments
(P < 0.05). Kyn in VIT−E hemodialysis patients was sig-
nificantly lower when compared to both BHD (P < 0.05)
and HDF (P < 0.05).
Figure 1 shows percent variation of IDO1 blood activ-
ity in different hemodialysis treatments compared to
controls.
Plasma nitric oxide
Data have been shown in Table 4. NO blood levels were
significantly lower in controls when compared to pa-
tients under any hemodialysis procedures. NO levels
were significantly higher in blood samples taken before
hemodialysis treatment, in BHD and HDF when com-
pared to VIT−E hemodialysis patients (P < 0.05). Sur-
prisingly, NO serum levels of blood sampled from the
venous line of VIT−E hemodialysis patients were signifi-
cantly lower when compared to the arterial blood sam-
pled from the same hemodialysis line. They were
measured simultaneously, throughout the same treat-
ment, at the end of the long interdialytic interval during
the last VIT−E period hemodialysis session, after 1−hour
VIT−E hemodialysis (Fig. 2). Percent reduction of ven-
ous vs arterial line was -22.6%. On the other hand, both
BHD and HDF NO concentrations in venous
hemodialysis line increased compared to arterial
hemodialysis line.
Figure 1 shows comparison among percent variations
of NO formation in all hemodialysis treatments and
controls.
Discussion
In the present study on chronic hemodialysis patients,
we have observed elevated IDO1 blood activity and the
Table 2 IDO1 activity in controls and all hemodialyzed patients
at the end of the study
CON (N = 14) HD patients (N = 18) P
Kyn, μmol/l 2.86 ± 0.81 6.62 ± 1.12 < 0.05
L − Trp, μmol/l 24.99 ± 3.37 18.12 ± 5.09 < 0.05
Kyn/Trp 12.74 ± 2.62 39.91 ± 4.36 < 0.01
IDO1, indoleamine 2,3-dioxygenase; CON, hospital staff healthy volunteers; HD,
hemodialysis; Kyn, kynurenine; L − Trp, L-tryptophan; Kyn/Trp, Kyn/ L-Trp ratio;
data are M ± SD
Table 3 IDO1 activity in hemodialyzed patients at the end of
each trial treatment period
BHD VIT − E HDF
Kyn, μmol/l 8.23 ± 1.57* 4.60 ± 1.63 6.81 ± 1.74*
L − Trp, μmol/l 17.90 ± 5.62 19.50 ± 5.42 17.22 ± 4.06
Kyn/Trp 45.81 ± 8.47* 23.58 ± 4.97 39.48 ± 6.13*
IDO1, indoleamine 2,3-dioxygenase; BHD, standard low−flux bicarbonate
hemodialysis with polysulfone membrane dialyzer; VIT − E, low−flux BHD with
vitamin E − loaded polysulfone membrane (Excebrane®) dialyzer; HDF,
hemodiafiltration with polysulfone membrane dialyzer; Kyn, kynurenine; L −
Trp, L-tryptophan; Kyn/Trp, Kyn/ L-Trp ratio; data are M ± SD; *, P < 0.05
vs VIT − E
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increase of NO serum levels when matched to healthy
individuals. These findings are consistent with published
data on uremic patients [20]. Previous results reported
that cellulose compared with more biocompatible syn-
thetic membranes such as modified cellulose (e.g.
Hemophan®) or polysulphone dialyzers, revealed a lower
reactive oxygen species production and higher vitamin E
in hemodialysis patients serum levels [35].
The limited number of hemodialysis patients included
is a clear study limitation. However, we observed that
stratifying our results according to the hemodialysis
treatment, VIT–E showed reduced IDO1 blood activity
and lower NO serum levels when compared to BHD and
HDF patients respectively. Our data also show signifi-
cantly reduced NO serum levels in VIT–E blood, sam-
pled just after vitamin E–coated membrane surface
contact, when compared to BHD and HDF blood sam-
ples. It is also relevant to observe that hemodialysis per-
formed by VIT−E was performed as standard low−flux
hemodialysis treatment, and solute clearance was not
subject to norm as it is in HDF procedures [36]. To the
best of our knowledge, this is the first description of
IDO1 blood activity and NO serum levels, analysed in
standard polysulfone low−flux hemodialysis with or
without vitamin E–coated membranes, and HDF.
IDO1 is an ever−present mammalian cytosolic enzyme re-
sponsible for catalysing the initial step of Trp catabolism.
Trp metabolism has also been identified as a metabolic
checkpoint of immuno−regulation, modulating T−cell be-
haviour including antimicrobial and antitumor defence, anti-
oxidant activity and suppression of autoimmunity. IDO1
activity is increased during hemodialysis, and it is believed
that IDO1 expression usually triggers macrophage
polarization towards the anti−inflammatory M2 anti−in-
flammatory phenotype [36]. However, solid data also show
that IDO1 cell overexpression decreasing Trp levels may
also lead to the production of toxic Kyn metabolites, pro-
moting the release of pro−inflammatory cytokines, polariz-
ing instead macrophages to the M1 pro−inflammatory
phenotype [37]. Moreover, a significant link has been found
between the increase of Kyn/Trp ratio values and the lower-
ing of vtamin E plasma levels [38]. If there is an IDO1 over-
expression in hemodialysis inflammaging, this may explain
the coexistence of uremic inflammation and increased im-
mune tolerance. We hypothesize that VIT−E, associated
with IDO1 down−regulation, reduces the total number of
Fig. 1 Average percent variation of blood IDO1 activity and serum NO formation in hemodialysis patients at the end of a long interdialytic
interval. IDO1, indoleamine 2,3-dioxygenase serum activity (kyn/L − trp); NO, nitric oxide (μmol/l); CON, hospital staff healthy volunteers; HD,
hemodialysis; BHD, standard low−flux bicarbonate hemodialysis by polysulfone membrane dialyzer; VIT − E, BHD with vitamin E − loaded
polysulfone membrane (Excebrane®) dialyzer; HDF, hemodiafiltration with polysulfone membrane dialyzer; *, P < 0.05 vs All HD, BHD, HDF
Table 4 NO serum levels (μmol/l) in controls and hemodialyzed
patients at the end of a 3 −month period long interdialytic
interval HD session. During the same hemodialysis treatment
blood was also drawn simultaneously, 60 min after the
beginning, from both arterial and venous blood lines




CON 40.3 ± 15.5^ N/A N/A
BHD 88.4 ± 24.7* 85.2 ± 26.9* 105.2 ± 34.3
VIT-E 70.6 ± 16.9 65.4 ± 21.6** 50.6 ± 32.4
HDF 91.5 ± 38.0* 87.7 ± 31.2* 97.1 ± 42.8
NO, nitric oxide; HD, hemodialysis; #, values at the beginning of the last HD
session after a 3 −month trial period; 60 −min arterial HD line, NO serum
levels from blood sampled from the arterial HD blood line 60min after the
beginning of a long interdialytic interval HD session at the end of the 3 −
month trial period; 60 −min venous HD blood line, NO serum levels from
blood taken from the venous HD blood line contemporarily drawn 60min
after the beginning of the last 3 −month period long interdialytic interval HD
session; CON, hospital staff healthy volunteers; N/A, not applicable; BHD,
standard low−flux bicarbonate HD with polysulfone membrane dialyzer; VIT −
E, BHD with vitamin E − loaded polysulfone membrane (Excebrane®) dialyzer;
HDF, hemodiafiltration with polysulfone membrane dialyzer; ^, P < 0.01 vs all
HD treatments; *, P < 0.05 vs VIT − E HD; data are M ± SD; **, P < 0.05 vs VIT − E
60 −min venous HD blood line from samples taken during the same
HD session
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activated M1− and/or M2−type macrophages, partially
adjusting hemodialysis innate immunity dysregulation. Our
data show that VIT−E reduces IDO1 blood activity,
confirming the acknowledged role vitamin E–loaded dia-
lyzers have in lowering hemodialysis inflammation [7]. It
also suggests VIT−E a role has in reducing hemodialysis
inflammaging.
Macrophage activation has been reported during the
course of hemodialysis, and its triggering results as the
main source of mammalian NO. High blood levels of NO
modulate not only the innate and adaptive immunity, but
also T and B cell differentiation and tumor resistance.
High plasma NO levels, have been reported in chronic
hemodialysis patients. NO is also produced during
hemodialysis, and is known to have a short half−life, as
well as showing serum level reduction after the passage of
blood through the hemodialysis hemofilter. The local
availability of abundant vitamin E anchored to dialysis
membrane may have been particularly effective in con-
trasting dialysis reactive oxygen species generation, and it
is important to hypothesize that vitamin E could interfere
on hemodialysis macrophage differentiation [38] in VIT−E
patients. Our data show that hemodialysis NO plasma for-
mation was significantly reduced after VIT−E treatment
when compared to BHD and HDF patients.
Inflammaging is a recently identified immune disorder
recognized as a new medical field of human aging, with
a growing incidence in metabolic diseases such as type II
diabetes and obesity, also related to the growing elderly
population worldwide [39]. Aging of the immune system
is associated with vaccination resistance, sepsis, and is
common in hemodialysis and chronic kidney disease.
Immune accelerate aging has instead been observed in
chronic inflammation disorders such as HIV, limitating
both innate and adaptive immunity [40]. We believe that
the accumulation of self−produced toxins in
hemodialysis patients, associated with long−term expos-
ure to hemofilter membranes as polysulfone, are highly
susceptible to chronic sterile low−grade inflammation,
accelerated immunosenescence as well as inflammaging.
IDO1 expression is known to induce the suppression of
effector T cells, promoting Treg activation and tolerance.
Recently, IDO1 activity has been identified as a potential
clinical marker of bacterial infection in hemodialysis pa-
tients [41], linking dysregulation of the immune system to
hemodialysis chronic microinflammation and risk of infec-
tion. Experimental data support the hypothesis that IDO1
suppresses innate and adaptive immune responses, con-
firming its relevance to promote chronic inflammatory
syndromes [42]. Elevated NO levels have also been found
in patients with chronic kidney disease [22]. NO is a rec-
ognized effector of innate and adaptive immune response,
modulating myeloid cell activities, and further promoting
chronic microinflammatory disorders [43].
Conclusions
We hypothesize that hemodialysis microinflammation in-
ducing accelerated immunosenescence and inflammaging
could be associated with susceptibility to infections, malig-
nancy and resistance to vaccination. Our data on
hemodialysis patients treated with VIT−E, suggest that low-
ering IDO1 activity and NO formation could partially pre-
serve immune system dysregulation during hemodialysis
inflammaging.
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